Patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) do not have a higher risk of major adverse cardiovascular events (MACE) with ertugliflozin, according to results of the phase III VERTIS CV* trial.
Patients who have undergone weight-loss surgery may sometimes have to return for revision, which helps improve outcomes associated with obesity, such as diabetes and hypertension, according to a meta-analysis.
Higher levels of plasma vitamin C, total and individual carotenoid biomarkers, and their composite biomarker score appear to reduce the incidence of type 2 diabetes (T2D), according to the results of a prospective case-cohort study in eight European countries.
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Remission of albuminuria may be an added benefit of undergoing Roux-en-Y gastric bypass (RYGB) in patients with type 2 diabetes (T2D), obesity, and early-stage chronic kidney disease (CKD), results of the MOMS* trial showed.
Greater consumption of total whole grains and commonly eaten whole grain foods, such as cereal, oatmeal, dark bread, brown rice, added bran, and wheat germ, substantially reduces the risk of type 2 diabetes (T2D), according to the results of three prospective cohort studies. On the other hand, eating one or more servings of popcorn a day is associated with an elevated risk of T2D.
Treatment with statins among individuals with type 2 diabetes, cardiovascular disease (CVD), or hypertension who are also positive for the novel coronavirus disease (COVID-19) must not be stopped unless there are specific contraindications, according to a study.
At the Novartis-sponsored VERIFY Soft Launch held at Le Meridien, Kuala Lumpur, two distinguished speakers spoke on the latest updates in glucose-lowering therapy and the benefit of early treatment intensification using combination therapy (ie, vildagliptin/metformin) in the management of T2DM.